相关实验视频
Updated: Jul 26, 2025

09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
9.5K
西斯普拉丁的耳毒性机制和对抗性干预策略:范围审查
Yingru Li1,2,3, Tianyang Zhang1,2,3, Qiang Song1,2,3
1Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, China.
Frontiers in cellular neuroscience
|June 16, 2023
概括
西斯普拉丁化疗是有效的,但会导致耳毒性和神经毒性. 这篇评论探讨了西斯丁.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 耳神经毒性 耳神经毒性
- 癌症化疗 癌症化疗
背景情况:
- 西斯普拉丁是治疗各种癌症的重要一线化疗,因为它的有效性和可负担性.
- 西斯的临床使用受到严重的耳毒性和神经毒性显著阻碍.
- 了解西斯的毒性机制对于改善患者的治疗结果至关重要.
研究的目的:
- 审查基底的分子机制,西斯普拉丁诱导的耳毒性.
- 讨论西斯普拉丁耐药性,细胞保护机制 (抗亡,线粒),以及它们的相互作用.
- 总结目前的预防策略和新型治疗药物用于西斯的耳毒性.
主要方法:
- 关于西斯普拉丁贩运,细胞毒性和保护性通路的综合文献综述.
- 对锡斯普拉丁耐药性和耳毒性机制的研究分析.
- 对潜在治疗干预措施的临床前研究的评估.
主要成果:
- 详细介绍西斯普拉丁进入内耳的途径及其对耳细胞的毒性作用.
- 鉴定抗亡和线粒细胞活化作为关键的保护机制.
- 对减轻西斯胺诱导的耳毒性有希望的临床前发现的概述.
结论:
- 西斯普拉丁的耳毒性是一种复杂的过程,涉及到细胞损伤和死亡途径.
- 在保护内耳细胞方面,抗亡和线粒消亡起着至关重要的作用.
- 对抗氧化剂和途径抑制剂等新型药物点进行进一步的研究是有必要的,以提高西斯治疗的安全性.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
252
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
252
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
209
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
209

